INDP Indaptus Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1857044 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.0%
TTM EPS YoY89.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-180.7%
ROA-70.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets66.9%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $9.34M | $7.25M | $7.62M | $6.32M | $2.52M |
| SG&A expense | $10.49M | $8.11M | $8.76M | $8.59M | $5.21M |
| Operating income | -$19.83M | -$15.37M | -$16.38M | -$14.91M | -$7.73M |
| Pretax income | -$20.85M | -$15.02M | — | — | — |
| Income tax | $1,716 | $1,700 | $2,450 | $30 | $1,650 |
| Net income | -$20.85M | -$15.02M | -$15.42M | -$14.32M | -$7.71M |
| EBITDA | — | -$15.37M | -$16.38M | -$14.91M | -$7.73M |
| EPS (basic) | -21.58 | -44.96 | -1.83 | -1.73 | -1.89 |
| EPS (diluted) | -21.58 | -44.96 | -1.83 | -1.73 | -1.89 |
| Weighted avg. shares (diluted) | 966,124 | 334,133 | 8.40M | 8.26M | 4.09M |
| Balance sheet | |||||
| Cash & equivalents | $8.51M | $5.79M | $13.36M | $9.63M | $39.13M |
| Short-term investments | — | — | — | $16.81M | — |
| Current assets | $9.31M | $6.62M | $14.00M | $27.24M | $40.39M |
| PP&E, net | — | — | $735 | $2,019 | $3,800 |
| Total assets | $9.31M | $7.34M | $14.92M | $28.06M | $40.58M |
| Current liabilities | $6.16M | $3.39M | $2.77M | $3.43M | $4.60M |
| Total liabilities | $6.16M | $3.39M | $2.85M | $3.43M | $4.68M |
| Shareholders' equity | $3.15M | $3.94M | $12.08M | $24.63M | $35.90M |
| Shares outstanding | 2.17M | 428,799 | 8.40M | 8.40M | 8.26M |
| Cash flow statement | |||||
| Operating cash flow | -$14.82M | -$12.32M | -$13.41M | -$13.08M | -$11.29M |
| Capital expenditure | — | — | — | — | $3,854 |
| Free cash flow | — | — | — | — | -$11.29M |
| Investing cash flow | — | — | $17.14M | -$16.43M | $447,746 |
| Financing cash flow | $17.54M | $4.75M | — | — | $48.34M |
| Depreciation & amortization | — | $735 | $1,284 | $1,781 | $1,403 |
| Stock-based compensation | $1.36M | $2.31M | $2.97M | $2.96M | $1.51M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.